You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Filters
Status
Categories
- Remove Advertising filter Advertising (2)
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Remove Biologicals filter Biologicals (2)
- Remove Complementary medicines filter Complementary medicines (7)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Manufacturing (1) Apply Manufacturing filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Remove Medicinal cannabis filter Medicinal cannabis (1)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (7) Apply Prescription medicines filter
- Scheduling (56) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove Biologicals filter Biologicals
- (-) Remove Medicinal cannabis filter Medicinal cannabis
- (-) Remove OTC medicines filter OTC medicines
- (-) Remove Advertising filter Advertising
- (-) Remove Complementary medicines filter Complementary medicines
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Sedating antihistamines
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Menthol
Closed on 18 May 2021
Proposal to remove redundant processes for entering certain formulation information into a therapeutic goods application
Closed on 24 February 2021
Potential reforms to medicinal cannabis manufacturing, labelling and packaging requirement
Closed on 29 January 2021
Discontinuing pre-market evaluation of Herbal Component Names (HCNs)
Closed on 12 January 2018
The Scheduling Policy Framework and Advertising of Pharmacist-only medicines (Schedule 3 substances)
Closed on 28 April 2017
Loratadine and desloratadine: proposed advisory statements for medicines
Closed on 7 December 2012
Fexofenadine and loperamide: proposed advisory statements for medicines
Closed on 4 June 2012
Regulation of new excipients in topical non-prescription medicines
Closed on 16 December 2005